METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE

Described are agents and methods for modulating an immune response. More particularly, described are various agents and methods for selectively regulating expression of the gene Il12b in live animals, including human patients. Aberrant expression of Il12b is associated with autoinflammatory diseases...

Full description

Saved in:
Bibliographic Details
Main Authors SMALE, Stephen T, DOTY, Kevin, SCUMPIA, Philip O, DAMOISEAUX, Robert D
Format Patent
LanguageEnglish
French
Published 13.04.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Described are agents and methods for modulating an immune response. More particularly, described are various agents and methods for selectively regulating expression of the gene Il12b in live animals, including human patients. Aberrant expression of Il12b is associated with autoinflammatory diseases including psoriasis, chronic eczema, vitiligo, lichen planus, systemic lupus erythematosus, Behçet's disease, and alopecia. Selective modulation of Il12b offers a new avenue for treatment of such diseases. L'invention concerne des agents et des procédés permettant de moduler une réponse immunitaire. Plus particulièrement, l'invention concerne divers agents et procédés permettant de réguler sélectivement l'expression du gène Il12b chez des animaux vivants, y compris des patients humains. L'expression aberrante d'Il12b est associée à des maladies auto-inflammatoires comprenant le psoriasis, l'eczéma chronique, le vitiligo, le lichen plan, le lupus érythémateux disséminé, la maladie de Behçet et l'alopécie. La modulation sélective d'Il12b offre un nouvel piste pour le traitement de telles maladies.
Bibliography:Application Number: WO2022US42200